Form 10-K

Overview

The report describes Capricor as a clinical-stage biotechnology company developing deramiocel and exosome-based therapeutics for Duchenne muscular dystrophy and other diseases. During 2024, it completed a BLA submission for deramiocel and reported $22,270,465 in consolidated revenue. At December 31, 2024, the company had 160 full-time employees and no products approved for commercial sale.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Publication date: 26 March 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services